.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
Mohali: ISAAC Luxe, a premium medical aesthetics and wellness brand, has expanded its national presence…
Chandigarh: The youth wing of Misl Satluj, a prominent socio-political organisation, has raised concerns over…
Mumbai: Actress Amruta Khanvilkar will soon appear in a new Netflix web series titled Taskaree,…
Mumbai: Actress Manushi Chhillar recently took to YouTube to share a rare glimpse into her…
Chandigarh: Renowned children’s book authors and storytellers have come together for the Paper Trails Literary…
Ranveer Singh, who tasted his share of failures with films such as “83”, “Jayeshbhai Jordaar”…